Ibere Pharmaceuticals Cl A (IBER)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5 | 93 | 135 | 458 | 680 |
| TOTAL | $113 | $276 | $327 | $693 | $972 |
| Non-Current Assets | |||||
| Investments And Advances | 138,842 | 138,109 | 138,020 | 138,017 | 138,012 |
| TOTAL | $138,842 | $138,109 | $138,020 | $138,017 | $138,012 |
| Total Assets | $138,955 | $138,385 | $138,348 | $138,710 | $138,984 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 159 | 159 | N/A | 0 | 0 |
| Accrued Expenses | 310 | 239 | 309 | 372 | 291 |
| TOTAL | $469 | $398 | $309 | $372 | $291 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 144,321 | 143,878 | 145,315 | 149,184 | 149,871 |
| TOTAL | $144,321 | $143,878 | $145,315 | $149,184 | $149,871 |
| Total Liabilities | $144,790 | $144,276 | $145,624 | $149,556 | $150,162 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 17,250 | 17,250 | 17,250 | 17,250 | 17,250 |
| Retained earnings | -5,835 | -5,891 | -7,276 | -10,846 | -11,178 |
| TOTAL | $-5,835 | $-5,891 | $-7,276 | $-10,846 | $-11,178 |
| Total Liabilities And Equity | $138,955 | $138,385 | $138,348 | $138,710 | $138,984 |